{"id":"NCT02739997","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)","officialTitle":"A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-08","primaryCompletion":"2017-07-28","completion":"2017-07-28","firstPosted":"2016-04-15","resultsPosted":"2018-07-12","lastUpdate":"2018-08-09"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Intra-abdominal Infection","Complicated Intra-abdominal Infection"],"interventions":[{"type":"DRUG","name":"MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)","otherNames":[]},{"type":"DRUG","name":"metronidazole 500 mg","otherNames":[]}],"arms":[{"label":"MK-7625A + metronidazole","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg for the treatment of Complicated Intra-abdominal Infections (cIAI) in Japanese participants. Efficacy will be primarily assessed by clinical response defined as complete resolution or significant improvement in signs and symptoms of the index infection.","primaryOutcome":{"measure":"Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC)","timeFrame":"Day 28 (28 days after initiating study therapy)","effectByArm":[{"arm":"MK-7625A + Metronidazole","deltaMin":92,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["40913503","30528561"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":100},"commonTop":["Aspartate aminotransferase increased","Alanine aminotransferase increased","Insomnia","Diarrhoea","Constipation"]}}